ArticleJournal of orthopaedic translation2026
Biomimetic nanodelivery of antagomiR-155-5p ameliorates wear particle-induced osteolysis by dual regulation of Gas6/Axl-mediated macrophage inflammation.
Article in Journal of orthopaedic translation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Aseptic loosening (AL) is the primary cause of prosthesis failure after total joint replacement, which is triggered by wear particle-induced macrophage activation, excessive inflammatory factor secretion and subsequent periprosthetic osteolysis. MicroRNAs (miRNAs) act as key regulators of this pathological cascade, yet the specific functional miRNAs and their precise regulatory mechanisms remain incompletely clarified. Methods: mRNA-seq and miRNA-seq were performed in titanium particle (TiPs)-stimulated macrophages to screen osteolysis-associated miRNAs, with expression validation conducted in clinical periprosthetic osteolytic tissues. In vitro functional and mechanistic assays were used to verify the miR-155-5p/Gas6/Axl regulatory axis, and a mouse calvarial osteolysis model was applied for in vivo validation. Macrophage membrane-camouflaged PLGA-PEI nanoparticles loaded with antagomir-155-5p (Anta-155@MNPs) were constructed, and their local therapeutic efficacy was evaluated in murine osteolysis models. Results: miR-155-5p was significantly upregulated in both TiPs-stimulated macrophages and clinical periprosthetic osteolytic tissues. Functionally, miR-155-5p promoted Stat1/p65 phosphorylation, proinflammatory cytokine production and M1 macrophage polarization by inhibiting the Gas6/Axl pathway via dual mechanisms: Mafb-mediated Gas6 transcriptional repression and Adam10-dependent Axl cleavage inhibition. In vivo, this axis exacerbated TiPs-induced calvarial osteolysis, while local Anta-155@MNPs administration markedly mitigated bone resorption and tissue inflammation. Conclusion: miR-155-5p drives TiPs-induced periprosthetic osteolysis via the Gas6/Axl signaling pathway, and targeted inhibition of miR-155-5p is a promising strategy to prevent artificial joint AL. The translational potential of this article: This study identifies the miR-155-5p/Gas6/Axl axis as a novel therapeutic target for AL, and the targeted Anta-155@MNPs delivery system provides a feasible preclinical strategy for clinical translation to treat wear particle-induced osteolysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.